Blumhouse Just Proved Low-Budget Horror Can Still Rule the Box Office in a Big Way

Horror has spent the past several years fighting to prove it can still move the needle at a box office increasingly dominated by nine-figure blockbusters. Few production companies have made that case more consistently than Blumhouse, the studio built on the philosophy that a scary enough idea doesn’t need a massive budget to become a genuine hit.

That philosophy paid off in a major way for Blumhouse Atomic Monster, the combined horror label formed through Jason Blum and James Wan’s 2024 merger, which has spent 2026 rebounding hard after a rough stretch of flops the previous year. Between fresh original concepts and long-running franchise entries, the studio built real momentum across the first eight months of the year without leaning on any single blockbuster-sized release.

According to Deadline, that momentum has now crossed a major threshold. Blumhouse Atomic Monster’s four major 2026 horror releases, ‘Obsession,’ ‘Backrooms,’ ‘Insidious: Out of the Further,’ and ‘Lee Cronin’s The Mummy,’ have collectively grossed north of $1 billion at the global box office year-to-date, pushed past the mark by ‘Insidious: Out of the Further’s’ $60 million global opening this past weekend.

What makes that milestone especially notable is just how little Blumhouse spent to get there. The four films were made on a combined production budget of only $50.75 million, a return of roughly 20 times their total cost within the first eight months of the year alone. ‘Obsession’ was financed for just $750,000 by Capstone, ‘Backrooms’ cost under $10 million through Chernin Entertainment and A24, Sony’s ‘Insidious: Out of the Further’ carried a net budget of $18 million, and New Line’s ‘Lee Cronin’s The Mummy’ came in at $22 million.

‘Obsession’ has emerged as the standout of the group, grossing $501.6 million worldwide according to Universal’s reporting, officially becoming the highest-grossing film in Blumhouse Atomic Monster’s history, as well as Focus Features’ all-time top earner, dethroning ‘Conjuring: The Last Rites’ and its $499.2 million total. Off its microbudget, the film has returned more than 650 times its production cost, making it the lowest-budgeted horror film to top the North American box office since 2009’s ‘Paranormal Activity,’ the film that originally helped establish Blumhouse’s entire business model.

This marks the second time Blumhouse Atomic Monster’s combined labels have crossed $1 billion since their 2024 merger, and the third time in four years that Blumhouse and Atomic Monster titles have collectively topped that mark when counting their pre-merger totals separately. In 2023, the two labels generated more than $1.07 billion worldwide combined across five releases, including ‘Five Nights at Freddy’s,’ ‘The Nun II,’ ‘Insidious: The Red Door,’ ‘M3GAN,’ and ‘The Exorcist: Believer.’

That track record stands in sharp contrast to 2025, when Blumhouse endured a genuine cold streak marked by underperforming titles like ‘M3GAN 2.0,’ ‘Wolf Man,’ ‘The Woman in the Yard,’ and ‘Drop,’ along with the cancellation of a planned ‘M3GAN’ spinoff. The turnaround began late last year with ‘Black Phone 2’ and ‘Five Nights at Freddy’s 2,’ continuing into this spring with ‘The Mummy’ reboot before this year’s full slate pushed the studio back into billion-dollar territory.

With ‘Insidious 6’ director Jacob Chase already set to reteam with Blumhouse Atomic Monster for the upcoming horror film ‘Sleepover,’ slated for a fall 2027 release, and sequels to ‘The Exorcist’ and ‘Paranormal Activity’ also on the way, the studio appears well-positioned to keep this momentum going well beyond 2026.

Have something to add? Let us know in the comments!